S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML) (H-28166): 

The purpose of this study is to determine the effects of adding Pravastatin to standard of care therapy (Idarubicin and Ara-C) for poor-risk AML. Patients must either have a previous diagnosis of AML that has relapsed after complete remission (CR) or complete remission with incomplete blood counts (CRi) that lasted less than six months or a previous diagnosis of MDS that has transformed to AML. All patients will receive the same treatment of induction and consolidation with Idarubicin, Ara-C and Prevastatin.

For additional information: http://www.clinicaltrials.gov/ct2/show/NCT00840177